---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-017065"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-05-02T23:59:59+00:00"
generated_at: "2026-06-26T02:20:23.708662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q1 net loss narrows to $3.3M; initiates strategic review

## Summary
- Net loss of $3.3M ($0.23/share) vs $4.1M ($0.33/share) in Q1 2021, narrowing on lower R&D spend.
- Cash $49.1M as of March 31, 2022, expected to fund operations through mid-2023.
- R&D expenses fell to $2.2M from $2.9M due to completion of rNAPc2 Phase 2b enrollment in Q4 2021.
- Board established Special Committee in April to evaluate strategic options including partnering or other alternatives.
- No revenue reported; clinical-stage biotech focused on genetically targeted cardiovascular therapies.

## SEC filing metadata
- accession: 0001564590-22-017065
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/0001564590-22-017065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022017065/abio-8k_20220502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-017065
- JSON: https://secwatch.observer/filing/0001564590-22-017065.json
- Plain text: https://secwatch.observer/filing/0001564590-22-017065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.